Osiris Therapeutics [OSIR] won a potential $224.7 million contract from the Defense Department for the development and possible purchase of Prochymal, an adult stem cell therapy, for the repair of gastrointestinal injury resulting from radiation exposure. Initially Osiris will receive $4.2 million this year to continue development of Prochymal for acute radiation syndrome (ARS). Once the Food and Drug Administration (FDA) approves the drug for ARS, the contract provides for the purchase of up to 20,000 doses, at $10,000 per…
Recommended
DIU Plans Demos Soon To Find Ground-Based, Long-Range Strike Systems To Scale Rapidly
Trending
Congress Updates
White House Details ‘Concerns’ With Shipbuilding, Spaced-Based Interceptor Oversight In House’s NDAA
The White House has detailed “a number of concerns” with the newly-passed House version of the next defense policy bill, to include the legislation’s limits on procuring Navy ships built […]
House Narrowly Votes To Pass $1.15 Trillion FY ‘27 NDAA, Blueprint For Reconciliation 3.0
The House on Wednesday narrowly voted to pass its $1.15 trillion version of the fiscal year 2027 National Defense Authorization Act (NDAA) and a blueprint for a third reconciliation bill […]
Senate Appropriators Press On Supplemental’s Requests Beyond Iran Scope, Hegseth Urges Full Funding
Senate appropriators have pressed Pentagon leadership on the decision to include funds in the Iran war supplemental request for items beyond the current military operation, while Defense Secretary Pete Hegseth […]
House Republicans’ Blueprint For Reconciliation 3.0 Includes $60 Billion For Defense
House Republicans on Wednesday unveiled a blueprint for a third reconciliation bill that includes $60 billion for defense, a figure slightly below the Trump administration’s request to cover Iran war […]